AKT1 and neoplasm: The extended use of rapamycin and its derivatives that target mTORC1, inevitably leads to the development of tumor-drug-resistance due to the elevated AKT activity.34 MK2206 was documented to inhibit all members of the AKT/mTOR pathway by previous reports.